SAB Biotherapeutics, Inc. (SABSW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
777 W 41ST ST MIAMI BEACH, FL 33140 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments, including: | 20,761 | 56,566 | 15,047 | 39,545 | 85 | |||
| Cash and cash equivalent | 8,898 | 56,566 | 15,047 | 33,207 | 85 | |||
| Short-term investments | 11,863 | |||||||
| Other undisclosed cash, cash equivalents, and short-term investments | 6,338 | |||||||
| Receivables | 5,557 | 8,011 | ||||||
| Prepaid expense | 1,494 | 2,636 | 2 | |||||
| Other undisclosed current assets | 3,032 | 2,341 | ||||||
| Total current assets: | 23,792 | 58,907 | 22,097 | 50,192 | 87 | |||
| Noncurrent Assets | ||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 3,583 | 3,670 | 3,897 | 4,019 | ||||
| Operating lease, right-of-use asset | 970 | 1,278 | 1,192 | 2,615 | ||||
| Property, plant and equipment | 15,368 | 19,737 | 23,251 | 24,314 | ||||
| Deferred costs | 235 | |||||||
| Other undisclosed noncurrent assets | 482 | 350 | 468 | |||||
| Total noncurrent assets: | 20,403 | 25,034 | 28,807 | 30,949 | 235 | |||
| TOTAL ASSETS: | 44,195 | 83,941 | 50,905 | 81,141 | 322 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 6,409 | 2,417 | 5,256 | 6,149 | 156 | |||
| Accounts payable | 1,695 | 946 | 3,679 | 4,459 | ||||
| Accrued liabilities | 4,714 | 1,472 | 1,577 | 1,690 | 156 | |||
| Deferred revenue | 1,322 | 100 | ||||||
| Debt | 418 | 1,183 | 905 | 1,958 | ||||
| Due to related parties | ✕ | ✕ | ✕ | 150 | ||||
| Other undisclosed current liabilities | 1,152 | 5,891 | 8,831 | 18,248 | ||||
| Total current liabilities: | 7,980 | 10,813 | 14,993 | 26,455 | 306 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 3,276 | 3,418 | 4,171 | 3,762 | ||||
| Long-term debt, excluding current maturities | 542 | |||||||
| Finance lease, liability | 3,276 | 3,418 | 3,630 | 3,762 | ||||
| Liabilities, other than long-term debt | 6,970 | 12,410 | 682 | 12,373 | ||||
| Operating lease, liability | 581 | 636 | 361 | 1,653 | ||||
| Derivative instruments and hedges, liabilities | 6,389 | 11,774 | 321 | 10,720 | ||||
| Total noncurrent liabilities: | 10,246 | 15,828 | 4,853 | 16,136 | ||||
| Total liabilities: | 18,226 | 26,642 | 19,847 | 42,591 | 306 | |||
| Equity | ||||||||
| Equity, attributable to parent | 25,970 | 57,299 | 31,058 | 38,550 | 16 | |||
| Preferred stock | 0 | 0 | ||||||
| Common stock | 1 | 1 | 5 | 4 | 0 | |||
| Treasury stock, value | (5,521) | (5,521) | (5,521) | |||||
| Additional paid in capital | 155,794 | 152,857 | 84,444 | 67,675 | 25 | |||
| Accumulated other comprehensive income (loss) | (135) | 26 | ||||||
| Accumulated deficit | (124,169) | (90,064) | (47,870) | (29,129) | (9) | |||
| Total equity: | 25,970 | 57,299 | 31,058 | 38,550 | 16 | |||
| TOTAL LIABILITIES AND EQUITY: | 44,195 | 83,941 | 50,905 | 81,141 | 322 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 1,322 | 2,239 | 23,904 | 60,876 | |||
| Gross profit: | 1,322 | 2,239 | 23,904 | 60,876 | |||
| Operating expenses | (44,233) | (40,314) | (52,822) | (74,269) | |||
| Operating loss: | (42,911) | (38,075) | (28,918) | (13,393) | |||
| Nonoperating income (expense) | 8,805 | (4,118) | 10,202 | 5 | |||
| Other nonoperating income | 2,453 | 435 | 34 | 5 | |||
| Interest and debt expense | (318) | (315) | (302) | 371 | |||
| Loss from continuing operations before equity method investments, income taxes: | (34,424) | (42,509) | (19,017) | (13,017) | |||
| Other undisclosed income (loss) from continuing operations before income taxes | 315 | 302 | (4,128) | ||||
| Loss from continuing operations before income taxes: | (34,424) | (42,194) | (18,715) | (17,145) | |||
| Income tax expense | (26) | ||||||
| Net loss: | (34,424) | (42,194) | (18,741) | (17,145) | |||
| Other undisclosed net income attributable to parent | 318 | ||||||
| Net loss available to common stockholders, diluted: | (34,105) | (42,194) | (18,741) | (17,145) | |||
Comprehensive Income ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (34,424) | (42,194) | (18,741) | (17,145) | |||
| Comprehensive loss: | (34,424) | (42,194) | (18,741) | (17,145) | |||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 1 | ||||||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 156 | 26 | |||||
| Comprehensive loss, net of tax, attributable to parent: | (34,267) | (42,167) | (18,741) | (17,145) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.